All results
8 results for randomized multicenter double blind placebo controlled parallel group phase 3 study
-
Clinical Trials
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing…
-
Clinical Trials
The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a…
-
Clinical Trials
160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for…
-
Clinical Trials
BLOCK-SAH is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial with a sequential parallel comparison design (SPCD) of…
-
Clinical Trials
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell…
-
News, Stories & Blog
Part 2 of our “Year in Review” focuses on the hospitals, research institutes and centers that are part of the UF Health family: UF Health Cancer Center UF…
-
News, Stories & Blog
The National Institutes of Health on Tuesday awarded a $38 million, five-year grant to Brian Hoh, M.D., M.B.A., the University of Florida’s chair of…
-
Clinical Trials
The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52…